Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT

1. Kharfan-Dabaja, M.A.
2. Labopin, M.
3. Bazarbachi, A.
4. Hamladji, R.M.
5. Blaise, D.
6. Socié, G.
7. Lioure, B.
8. Bermudez, A.
9. Lopez-Corral, L.
10. Or, R.
11. Arcese, W.
12. Fegueux, N.
13. Nagler, A.
14. Mohty, M.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1038/BMT.2014.133 GOOGLE SCHOLAR lock_openOpen access editor